Inhibitory effect of arsenic trioxide on angiogenesis and expression of vascular endothelial growth factor in gastric cancer

Yan-Feng Xiao, Shan-Xi Liu, De-Dong Wu, Xi Chen, Li-Fen Ren

Abstract

AIM: To investigate the inhibitory effect of As$_2$O$_3$ on angiogenesis of tumor and expression of vascular endothelial growth factor (VEGF) in tumor cells in vivo and in vitro.

METHODS: The solid tumor model was formed in nude mice with the gastric cancer cell line SGC-7901. The animals were randomly divided into three groups. As$_2$O$_3$ was injected into the arsenic-treated groups (2.5 mg/kg and 5 mg/kg) and the same volume of saline solution was injected into the control group. Microvessel density (MVD) and expression of VEGF were detected with immunofluorescence laser confocal technology. Further expression of VEGF protein and VEGF mRNA was measured with Western blotting and fluorescence quantitative RT-PCR in SGC-7901 cells treated with As$_2$O$_3$.

RESULTS: In nude mice, after treatment with 5 mg/kg and 2.5 mg/kg As$_2$O$_3$ respectively, about 50% and 30% tumor growth inhibition were observed correspondingly (P < 0.05, P < 0.05). Decrease in MVD appeared in S203-treated tumors compared with control group (P < 0.001, P < 0.001). MVD in tumors was significantly lower in 5 mg/kg group than in 2.5 mg/kg group (P < 0.01). The fluorescence intensity levels of VEGF in tumor cells were significantly lower in the arsenic-treated groups (P < 0.01, P < 0.01). The fluorescence intensity level of VEGF in 5 mg/kg group was lower than that in 2.5 mg/kg group (P < 0.01). In vitro, the expression of VEGF protein decreased in dose- and time-dependent manner after the treatment with As$_2$O$_3$, but in VEGF mRNA no significant difference was found between the control group and the treated groups.

CONCLUSION: As$_2$O$_3$ can inhibit solid tumor growth by inhibiting the formation of new blood vessels. One of the mechanisms is that As$_2$O$_3$ can inhibit VEGF protein expression.

© 2006 The WJG Press. All rights reserved.

Key words: Arsenic trioxide; Vascular endothelial growth factor; Angiogenesis; Tumor growth inhibition

INTRODUCTION

Arsenic has been used since ancient times as a therapeutic agent. However, until recently its use in modern medicine has been restricted to the treatment of a limited number of parasitic infections. Since the early 1990s, arsenic trioxide (As$_2$O$_3$) has been used successfully in the treatment of patients with relapsed and refractory acute promyelocytic leukemia (APL)[1,2]. As$_2$O$_3$ has been shown to cause degradation of PML-RAR alpha, promoting differentiation[3,4]. However, degradation of PML-RAR alpha may not be wholly responsible for the great sensitivity of APL cells to As$_2$O$_3$. Other investigations subsequently found that As$_2$O$_3$ can induce apoptosis of APL cells, other malignant myeloid, lymphoid, and megakaryocytic cells.

The mechanism by which arsenic exerts effect of inhibiting tumor still remains uncertain. Investigations of arsenic have found that its efficacy is dependent upon a number of mechanisms. Arsenic may affect numerous intracellular signal transduction pathways and causes many alterations in cellular function[5-8]. Recently, it has been reported that As$_2$O$_3$ can decrease microvessel density and inhibit angiogenesis in solid tumors[9,10], but its pathway is
Angiogenesis is an important factor in the progression and enlargement of solid neoplasms and is in close relation to invasion and metastases \cite{12-14}. Angiogenesis can be divided into a series of temporally regulated responses, including protease induction, endothelial cell migration, proliferation and differentiation \cite{13}. This process begins with the production and release of angiogenic factors by endothelial cells, tumor cells and matrix cells. Vascular endothelial growth factor (VEGF) produced by tumor cells is a potent angiogenic factor, and it binds to endothelial cell surface receptors and activates various functions of the cells \cite{16-19}. Therefore, angiogenesis can be reflected by the expression of VEGF.

In the present report, we investigated the inhibitory effect of As$_3$O$_3$ on angiogenesis of tumor and expression of VEGF in tumor cells in vivo and in vitro. The solid tumor model was formed in nude mice with the gastric cancer cell line SGC-7901. Microvessel density (MVD) and expression of VEGF were detected by immunofluorescence laser confocal technology. In vitro we measured further expression of VEGF protein and VEGF mRNA with Western blots and real-time fluorescence quantitative RT-PCR.

**MATERIALS AND METHODS**

**Animals and cells**

Thirty 5-wk-old male BALB/C-nu/nu mice weighing 19-21 g were purchased from Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai, China. Mice were acclimatized at the Animal Laboratory Centre of the Fourth Military University for 1 wk before receiving injections of cancer cells. The mice were kept in a laminar-filtered airflow cabinet under pathogen-free conditions with a constant temperature of 22 ± 2°C, relative humidity of 55% ± 5% and 12-h dark/light cycles. All experiments were carried out according to the guidelines of the Laboratory Protocol of Animal Handling of the Fourth Military Medical University. Human gastric cancer cell line, SGC-7901, was purchased from the Animal Laboratory Centre of the Fourth Military Medical University. SGC-7901 cells were cultured in RPMI 1640 medium supplemented with 100 mL/L fetal bovine serum (FBS) at 37°C in a 50 mL/L CO$_2$ incubator.

**Drug and instruments**

Arsenious acid [H$_3$AsO$_3$ (As$_2$O$_3$ + 3H$_2$O ⇄ H$_3$AsO$_3$)] was supplied by Yida Pharmaceutical Co, Harbin, China. VEGF expression in tumor xenografts was examined by a TCS SP2 laser confocal microscope made by LEICA Co, Germany. VEGF mRNA was examined by real time system ABI7000 (Applied Biosystems, Foster City, CA, USA).

**Xenografts in nude mice and treatment**

Thirty mice received sc injection into the right flanks with a 200 μL cell suspension containing 2 × 10$^7$ SGC-7901 cells. After 10 d, when established tumors of 0.2-0.3 cm$^3$ diameter were detected, drug administration was started. The animals were randomly divided into three groups consisting of 10 animals in each. Arsenious acid diluted with 9 g/L saline solution was injected into the peritoneal cavum every day to the two treatment groups (2.5 mg As$_3$O$_3$/kg and 5 mg As$_3$O$_3$/kg in 0.2 mL) and the same volume of 9 g/L saline solution was injected to the control group. After 10 d of treatment, the three groups of mice were sacrificed and the tumor masses were removed. After the weights of tumor mass were measured, the tumor mass was fixed in 40 g/L paraformaldehyde and frozen sections prepared with a cryostat (HM505E Cryomicrot, Germany) for immunofluorescence analysis. The liver and kidneys were prepared for paraffin sections routinely for pathological examination.

**Inhibition of tumor growth**

Tumor growth inhibition (TGI) was used to assess the therapeutic efficacy against xenografts. The tumor weight was to calculate TGI, that is, TGI (%) = (1 - W/t / W/c) × 100%, where W/t is the mean tumor weight of the arsenic-treated group, W/c is the mean tumor weight of the control group. Tumor growth inhibition was expressed by tumor volumes that were measured before treatment and 6 and 11 d after treatment respectively. Tumor volume expressed as cm$^3$ is calculated using the formula: tumor volume = 1/2(ab), where a is the long axis, b is the short axis. TGI (%) = (1 - V/t/V/c) × 100%, where V/t is the mean tumor volume of the arsenic-treated group, V/c is the mean tumor volume of the control group.

**Immunofluorescence examination**

CD31 antigen was used as an immunofluorescence marker of vessel endothelial cells. For the immunofluorescent staining of CD31 and VEGF, the frozen sections were kept at room temperature for 30 min, incubated in distilled water for 5 min and in PBS for 5 min, permeabilized in 1 g/L Triton-X-100 for 10 min, washed with PBS (5 min × 3), blocked with 100 mL/L sheep serum (Sigma) at 37°C for 20 min, incubated in the primary antibody, rat anti-mouse CD31 (Biologend, USA) or rabbit anti-human VEGF polyclonal antibody (Labvision, USA) at 4°C overnight, washed with PBS (5 min × 3), incubated in the secondary antibody (goat anti-rat IgG conjugated TRITC or sheep anti-rabbit IgG conjugated FITC, Sigma) for 1 h at 37°C, washed with PBS (10 min × 3) and then examined under a TCS SP2 laser confocal microscope.

For each group, several field images of VEGF in each tumor tissue section were captured under confocal microscope, fluorescence intensity of each section in the confocal fluorescence images was measured using the Leica Confocal analysis system. The mean fluorescence intensity in each section was then calculated.

**Assessment of microvessel density**

Microvessel density (MVD) was determined under a confocal microscope in the area of tumor tissue sections. The microvessels were carefully counted on 20 fields (× 400). The mean and SE were expressed as the number of microvessels identified within the area.

**Cell culture and administration of As$_3$O$_3$ in vitro**

SGC-7901 cells were cultured in RPMI 1640 medium with 100 mL/L FBS, 100 KU/L penicillin and 100 mg/L streptomycin and...
were cultured at 37°C in a 50 mL/L CO₂ humidified atmosphere. SGC-7901 cells in logarithmic growth phase were inoculated in culture medium, without adding (control group) and adding As₂O₃ according to different concentrations of below 0.5, 1, 2 and 3 μmol/L. The tumor cells were collected respectively at 24 h, 48 h and 72 h for Western blot of VEGF. The fluorescent quantitative RT-PCR of VEGF was analyzed in the tumor cells collected at 48 h.

**Western blotting for VEGF**

After treatment with As₂O₃, SGC-7901 cells were washed with ice-cold PBS and dissolved with lysis buffer (1 mmol/L NaVO₃, 0.017 g/L aprotinin, 2 mmol/L PMSF, 25 μmol/L P-N-P, 0.1 g/L leupeptin, 10 g/L NP-40, 0.15 mol/L NaCl, 0.02 mol/L Tris HCl, 0.1 g/L NANA). The protein lysates were centrifuged at 12000 r/min for 10 min at 4°C. The protein lysates were mixed with 5 × sample buffer, boiled for 10 min, and analyzed by 120 g/L sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). After SDS-PAGE, the gel was transferred to a 0.45-μm pure nitrocellulose membrane. The membrane was blocked with 5 mL/L skim milk in TBS-Tween 20 for 1 h at room temperature, and reacted with mouse anti-human VEGF monoclonal antibody (Santa Cruz) at 4°C overnight. The membrane was then incubated with the secondary antibody (rabbit anti-mouse IgG). The protein content was visualized using HRP-conjugated secondary antibodies, followed by enhanced chemiluminescence (ECL).

**Fluorescence quantitative RT-PCR for VEGF**

RT-PCR for VEGF, total RNA was extracted from tumor cells using Trizol reagent according to the manufacturer's protocol (Promega, Madison, WI, USA). RNA was reversely transcribed to cDNA by the kit (Promega, Madison, WI, USA). Prime and probe were designed with the assistance of Primer Express 2.0. MGB-TaqMan probe of VEGF (VEGF-FAM): 5'-ACCATGCAGATTAGTG-3'. For VEGF, the following primers were used: 5'-GGGGACCTGAGGAGTCCAACA-3', 5'TGGCCCTTG-GTGGATTGTGTAG-3'. MGB-TaqMan probe of β-actin (HBA-TAMRA-FAM): 5'CCAGGGGGTGATGGTG-GCAT-3'. For β-actin the following primers were used: HBA-TAMRA-FP 5'GCTCTTCTCCCTCCATCG 3' HBA-TAMRA-RP 5'GTCGCAGTGGTGACAGATGC 3' The primes and probes were synthesized by Shanghai GeneCore BioTechnologies Co., Ltd. All PCR reactions were performed on a real time system ABI7000 (Applied Biosystems, Foster City, CA, USA). The thermal cycle conditions comprised 2 min at 50°C, 10 min at 95°C, 30 s at 95°C and 30 s at 60°C. Each PCR run included five points of calibration curve (5 samples were obtained by tenfold serially dilutions of standard product, and the standard curve was established from the 5 samples for the determination of the relative quantity of genes), a non-template control, and the respective sample cDNA.

**Statistical analysis**

The data were represented as mean ± SD. The data was analyzed with statistical software of SPSS10.0. Multiple statistical comparisons were performed using ANOVA in a multivariate linear model. Student's t test was used to assess differences between the treatment group and control group. P < 0.05 was considered statistically significant.

**RESULTS**

**Inhibition of tumor growth by arsenic trioxide**

All nude mice developed tumor after 10 d in implantation of SGC-7901 cells. When drug administration was started, there was no significant difference in the tumor volume of the three groups (P > 0.05). The increase in tumor volume and weight in the three groups from d 0 to 11 after treatment is shown in Table 1. Tumor volume growth of 2.5 mg/kg or 5 mg/kg of the arsenic-treated group was reduced by 30.3% or 50.9% after 10 d administration of arsenic trioxide. Tumor weight growth was inhibited by 29.1% and 52.2% respectively in the 2.5 mg/kg and 5 mg/kg arsenic -treated group. There were statistical differences in the tumor volumes and weights in the arsenic -treated group (2.5 mg/kg group and 5 mg/kg group) and control (P < 0.05). On the other hand, the tumor volumes and weights in the 5 mg/kg group were significantly less than that in the 2.5 mg/kg group (P < 0.05). No obvious toxic effects attributable to As₂O₃ therapy were noted. The body weight of the mice was not affected. All of the 30 studied mice were alive at the end of treatment. HE staining of the nude mice's liver and kidney did not reveal pathological changes.

**Inhibition of tumor angiogenesis by arsenic trioxide**

Sections from the mice in all three treatment groups were stained for CD31 immunofluorescence to detect the number of endothelial cells (ECs) as a measure of tumor angiogenesis. A single microvessel was defined as any immunofluorescence stained endothelial cell distinguished from adjacent tumor cells and other connective tissue elements. Microvessel density as a parameter of angiogenic activity was decreased in tumors of experimental groups treated with 2.5 mg/kg (Figure 1B) and 5 mg/kg arsenic trioxide (Figure 1C). Microvessel density of arsenic-treated groups was significantly lower than that of the control group (Figure 1A). Significantly fewer microvessel density was present in the 5 mg/kg group than that in the 2.5 mg/kg group. These studies demonstrated the decreased capillary density of the tumor with treatment of As₂O₃ (Table 2).

**Effect of arsenic trioxide on expression of VEGF in vivo**

Expression of VEGF was confirmed by the presence

| Group | Tumor volume (V) mm³ | Mass (mg) | TGI (%) |
|-------|---------------------|----------|---------|
| D₀    | 343 ± 160          | 999 ± 338 | 784 ± 185 |
| D₆    | 307 ± 80           | 303 ± 160 | 343 ± 116 |
| D₁₁   | 343 ± 160          | 999 ± 338 | 784 ± 185 |

*P < 0.05 vs control; †P < 0.05 vs 2.5 mg/kg; TGI calculated using tumor volume was given in parenthesis.
of fluorescence-stained cytoplasm in the tumor cells. It is shown in Figure 2, strong immunoreactivity to VEGF was found in all the SGC-7901 tumor xenografts of the control group (Figure 2A). The weaker fluorescence intensity expression was observed in SGC-7901 tumor of the groups treated with 2.5 and 5 mg/kg arsenic trioxide (Figure 2B and C). The fluorescence intensity levels of VEGF in tumor cells were significantly lower in the arsenic-treated groups than in control group \((P < 0.01)\). The fluorescence intensity level of VEGF in 5 mg/kg group was lower than that in 2.5 mg/kg \((P < 0.01, \text{Table 2})\).

**Figure 2** VEGF expression in xenograft tumor. Original magnification \(\times 400\). A: Control group; B: 2.5 mg/kg group; C: 5 mg/kg group. The fluorescence expression of VEGF in tumor cells were decreased in the arsenic-treated groups.

| Group   | MVD    | VEGF   |
|---------|--------|--------|
| Control | 9.32 ± 0.33 | 49.23 ± 2.12 |
| 2.5 mg/kg | 5.36 ± 0.32  | 20.07 ± 1.19μ |
| 5 mg/kg | 3.05 ± 0.24bd | 11.93 ± 1.07μd |
| F       | 111.841 | 163.461 |
| P       | < 0.001 | < 0.001 |

\(^{1}P < 0.01\) vs Control; \(^{2}P < 0.01\) vs 2.5 mg/kg.

### Table 2 Effect of As2O3 on microvessel density and VEGF expression in tumor xenografts (\(n = 10\), mean ± SD)

### Table 3 Effect of As2O3 on VEGF mRNA in SGC-7901 cell by real time RT-PCR

| As2O3 (μmol/L) | VEGF mRNA | β-actin mRNA | VEGF mRNA/β-actin mRNA |
|---------------|------------|--------------|-------------------------|
| 0             | 1.28 × 10⁶ | 3.72 × 10⁷   | 3.44 × 10⁻³               |
| 0.5           | 2.34 × 10⁵ | 7.92 × 10⁶   | 2.95 × 10⁻²               |
| 1.0           | 4.74 × 10⁵ | 9.96 × 10⁶   | 4.76 × 10⁻²               |
| 2.0           | 2.16 × 10⁵ | 7.24 × 10⁶   | 2.89 × 10⁻²               |
| 3.0           | 3.21 × 10⁴ | 8.2 × 10⁶   | 3.91 × 10⁻²               |

of fluorescence-stained cytoplasm in the tumor cells. It is shown in Figure 2, strong immunoreactivity to VEGF was found in all the SGC-7901 tumor xenografts of the control group (Figure 2A). The weaker fluorescence intensity expression was observed in SGC-7901 tumor of the groups treated with 2.5 and 5 mg/kg arsenic trioxide (Figure 2B and C). The fluorescence intensity levels of VEGF in tumor cells were significantly lower in the arsenic-treated groups than in control group \((P < 0.01)\). The fluorescence intensity level of VEGF in 5 mg/kg group was lower than that in 2.5 mg/kg \((P < 0.01, \text{Table 2})\).

**Effect of arsenic trioxide on expression of VEGF mRNA and protein in SGC-7901 cell line in vitro**

To further analyze the effect of arsenic trioxide on VEGF expression in tumor, we assessed VEGF expressions of SGC-7901 cells in vitro using Western blotting and fluorescent quantitative RT-PCR. Western blot analysis revealed that the expression of VEGF protein decreased in a dose- and time-dependent manner after treatment with As2O3 (Figure 3). But VEGF mRNA expression was not in agreement with the VEGF protein expression results, VEGF mRNA data did not reveal a significant difference between the control group and the treatment groups (Table 3, Figures 4 and 5).

**DISCUSSION**

The development of a growing tumor requires an abundant blood supply. Angiogenesis is an important factor in the progression and enlargement of solid neoplasms and close relation to invasion and metastases\(^{12-14}\). Vascularisa-
tion within the primary tumor has a direct relation with the tumor growth rate. Inhibition of angiogenesis may lead to control of tumor growth and metastasis, therefore, antiangiogenesis is a promising therapeutic approach for treatment of cancer\cite{20-22}. The results presented here indicated that As$_2$O$_3$ is active against angiogenesis in vivo and in vitro. We examined the effect of As$_2$O$_3$ on angiogenesis in a human tumor model in nude mice. The result showed that subcutaneous injection of SGC-7901 cells yielded a 100% tumor uptake rate. About 50% and 30% SGC-7901 tumor growth inhibition was following treatment of As$_2$O$_3$ with 5 mg/kg and 2.5 mg/kg separately.

We measured the MVD in tumor tissues by labeled CD31, which marked endothelial cells of microvessels. Decrease of the MVD in tumor tissue was related to treatment of As$_2$O$_3$. A high degree of tumor angiogenesis was observed in mice without treatment of As$_2$O$_3$, but MVD was low in As$_2$O$_3$-treated tumors. There was a significant difference in MVD between the control group and treatment groups. MVD was significantly lower in the high dosage group with 5 mg/kg As$_2$O$_3$ than in the low dosage group with 2.5 mg/kg. Our observation was in agreement with the results of Shen\cite{9}. This study demonstrated that As$_2$O$_3$ induced a dose-dependent decrease of MVD, accompanied by inhibition of tumor growth. These suggest that induction of angiogenesis is an important step in carcinogenesis and As$_2$O$_3$ inhibits tumor growth by, at least in part, decreasing intratumor MVD.

It has been reported that neovascularization is regulated by accelerators, such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (FGF), hepatocyte growth factor (HGF), thymidine phosphorylase, endothelin, IL-4, and IL-8, and by inhibitors such as thrombospondin, endostatin, angiostatin, transforming growth factor-\(
\beta_1\) (TGF-\(
\beta_1\)), tumor necrotic factor (TNF) and IL-6\cite{23}. Of these factors, VEGF is involved very much in the proliferation and metastasis of various cancers. There is evidence that the degree of several surrogate angiogenic markers such as microvessel density or (VEGF) expression levels in primary tumor tissue can reflect the biological aggressiveness of tumors and provide prognostic information\cite{18,23-25}.

The VEGF gene family currently includes six members: VEGF-A (prototype VEGF), VEGF-B, VEGF-C, VEGF-D, VEGF-E and placenta growth factor. Of them, vascular VEGF, also known as vascular permeability factor, is a potent angiogenic cytokine that induces mitosis and also regulates permeability of endothelial cells. In addition, VEGF prolongs the survival of new blood vessels by inducing the expression of Bcl-2 protein. VEGF plays a crucial role in vasculogenesis and angiogenesis, and is closely related to invasion and metastases of tumors\cite{26,27}.

Several studies reported that the degree of VEGF expression in tumors correlated positively with the level of MVD, the degree of malignancy, stage of tumor, presence/absence of peritoneal dissemination and metastases, and correlated negatively with prognosis\cite{12,23,28}. In the present study, high expression VEGF existed in tumor tissues without treatment of As$_2$O$_3$, which also showed an increase of MVD, suggesting that VEGF is
most closely associated with induction and maintenance of the neovascularization in human gastric cancer. Since human gastric cancer SGC-7901 cells secrete high amounts of VEGF and develop in nude mice tumors whose growth is highly VEGF-dependent, they provide a good model to test the availability of molecules that inhibit VEGF bioactivity.

In recent years, it has been widely shown that VEGF activity is a key feature during tumor growth and angiogenesis, and that blocking of this signal transduction pathway may inhibit tumor progression. In vitro, VEGF acts as a potent mitogenic factor for endothelial cells and as blood vessel permeabilising agents34. Our in vitro study indicated that expression of VEGF was significantly reduced after As2O3 treatment, which demonstrated that As2O3 can inhibit VEGF expression. The formation of new blood vessels is inhibited due to suppression of tumor cell secretion of VEGF by As2O3.

We further explored the mechanism of the inhibitory action of As2O3 on VEGF in tumor cells in vitro. We measured expression of VEGF protein and VEGF mRNA in the SGC-7901 cell line with Western blots and real time RT-PCR separately. The results showed that As2O3 induced a dose-and time-dependent down-regulation of VEGF protein expression in the SGC-7901 cell line, but did not affect VEGF mRNA expression. The results reveal the effect of As2O3 on VEGF expression on the protein level rather than the mRNA level.

These studies have demonstrated that As2O3 can inhibit solid tumor growth in vitro, possibly by inhibiting the formation of new blood vessels. One of the mechanisms is that As2O3 can inhibit VEGF protein expression. These results may be useful in devising better strategies for cancer treatment.

REFERENCES

1. Wang ZY. Arsenic compounds as anticancer agents. Cancer Chemother Pharmacol 2001; 48 Suppl 1: S72-S76
2. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-3360
3. Slack JL, Waxman S, Tricot G, Tallman MS, Bloomfield CD. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide. Oncologist 2002; 7 Suppl 1: 1-13
4. Davison K, Mann KK, Miller WH Jr. Arsenic trioxide: mechanisms of action. Semin Hematol 2002; 39: 3-7
5. Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncologist 2001; 6 Suppl 2: 3-10
6. Murojo AJ. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist 2001; 6 Suppl 2: 22-28
7. Miller WH Jr. Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002; 62: 3893-3903
8. Miller WH Jr. Molecular targets of arsenic trioxide in malignant cells. Oncologist 2002; 7 Suppl 1: 14-19
9. Shen ZY, Shen J, Chen MH, Wu XY, Wu MH, Zeng Y. The inhibition of growth and angiogenesis in heterotransplanted esophageal carcinoma via intratumoral injection of arsenic trioxide. Oncol Rep 2003; 10: 1869-1874
10. Griffin R, Lee SH, Rood KL, Stewart MJ, Lyons JC, Lew YS, Park H, Song CW. Use of arsenic trioxide as an antivascular and thermosensitizing agent in solid tumors. Neoplasia 2000; 2: 555-560
11. Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell RP Jr, Rafii S. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelial cells and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000; 96: 1525-1530
12. Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol 2003; 13: 159-167
13. Dekel Y, Koren R, Kugel V, Livne PM, Gal R. Significance of angiogenesis and microvascular invasion in renal cell carcinoma. Pathol Oncol Res 2002; 8: 129-132
14. Edel MJ, Harvey JM, Papadimitriou JM. Comparison of vascularity and angiogenesis in primary invasive mammary carcinomas and in their respective axillary lymph node metastases. Clin Exp Metastasis 2000; 18: 695-702
15. Klagsbrun M, Moses MA. Molecular angiogenesis. Chem Biol 1999; 6: R217-R224
16. McCabe CJ, Boelaert K, Tannahl LH, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklin JA, Gittoes NJ. Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 2002; 87: 4238-4244
17. Zhang H, Wu J, Meng L, Shou CC. Expression of vascular endothelial growth factor and its receptors KDR and Flt-1 in gastric cancer cells. World J Gastroenterol 2002; 844-998
18. Ghannem MA, van Steenbrugge CJ, Sudarikov MK, Mathoera RS, Nijman JM, van der Kwast TH. Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblasta. J Clin Pathol 2003; 56: 107-113
19. Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melissi D, De Vita F, De Placido S, Bianco AR, Tortora G. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiproliferative growth factor receptor therapy. Clin Cancer Res 2004; 10: 784-793
20. Jung YD, Kim MS, Shin BA, Chay KO, Ahn BW, Liu W, Bucana CD, Gallick GE, Ellis LM. EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. Br J Cancer 2001; 84: 844-850
21. Sharma RA, Harris AL, Dalgleish AG, Steward WP, O’Byrne KJ. Angiogenesis as a biomarker and target in cancer chemoprevention. Lancet Oncol 2001; 2: 726-732
22. Ranieri G, Gasparini G. Angiogenesis and angiogenesis inhibitors: a new potential anticancer therapeutic strategy. Curr Drug Targets Immune Endocr Metabol Disord 2001; 1: 241-253
23. Yabushita H, Shimazu M, Noguchi M, Kishida T, Narumiya H, Sawaguchi K, Noguchi M. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer. Oncol Rep 2003; 10: 89-95
24. Ranieri G, Passantino L, Patruno R, Passantino G, Jirillo F, Catino A, Mattioli V, Gadaleta C, Ribatti D. The dog mast cell tumour as a model to study the relationship between angiogenesis, mast cell density and tumor malignancy. Oncol Rep 2003; 10: 1189-1193
25. Ranieri G, Coviello M, Chiratti A, Stea B, Montemurro S, Quaranta M, Dittadi R, Paradiso A. Vascular endothelial growth factor assessment in different blood fractions of gastrointestinal cancer patients and healthy controls. Oncol Rep 2004; 11: 435-439
26. Poon RT, Lau C, Yu WC, Fan ST, Wong J. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma.
a prospective study. *Oncol Rep* 2004; **11**: 1077-1084

27 Faviana P, Boldrini L, Spisni R, Berti P, Galleri D, Biondi R, Camacci T, Materazzi G, Pingitore R, Miccoli P, Fontanini G. Neoangiogenesis in colon cancer: correlation between vascular density, vascular endothelial growth factor (VEGF) and p53 protein expression. *Oncol Rep* 2002; **9**: 617-620

28 Cascinu S, Staccioli MP, Gasparini G, Giordani P, Catalano V, Ghiselli R, Rossi C, Baldelli AM, Graziano F, Saba V, Muretto P, Catalano G. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. *Clin Cancer Res* 2000; **6**: 2803-2807

29 Hamma-Kourbali Y, Starzec A, Vassy R, Martin A, Kraemer M, Perret C, Crépin M. Carboxymethyl benzylamide dextran inhibits angiogenesis and growth of VEGF-overexpressing human epidermoid carcinoma xenograft in nude mice. *Br J Cancer* 2003; **89**: 215-221